Market capitalization | $10.77m |
Enterprise Value | $-6.52m |
P/E (TTM) P/E ratio | 1.86 |
EV/FCF (TTM) EV/FCF | 0.37 |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-19.07m |
Free Cash Flow (TTM) Free Cash Flow | $-17.53m |
Cash position | $17.29m |
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
1 Analyst has issued a forecast Minerva Neurosciences Inc:
1 Analyst has issued a forecast Minerva Neurosciences Inc:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -19 -19 |
22%
22%
|
EBIT (Operating Income) EBIT | -19 -19 |
22%
22%
|
Net Profit | 6.25 6.25 |
120%
120%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Rémy Luthringer |
Employees | 8 |
Founded | 2007 |
Website | www.minervaneurosciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.